Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)

Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)

Introduction Imeglimin is a novel anti-hyperglycemic drug that improves both insulin resistance and insulin secretion. The effects of imeglimin on glycemic control were confirmed in phase III clinical trials, but little is known about its effectiveness in daily clinical practice settings, especially...

Full description

Bibliographic Details
Main Authors: Kyu Yong Cho, Tatsuya Atsumi, Hiroshi Nomoto, Jun Takeuchi, So Nagai, Akinobu Nakamura, Hideaki Miyoshi, Shinji Taneda, Aika Miya, Hiraku Kameda, Akihiro Takahashi, Hiroyoshi Kurihara
Format: Article
Language:English
Published: BMJ Publishing Group 2022-12-01
Series:BMJ Open Diabetes Research & Care
Online Access:https://drc.bmj.com/content/10/6/e002988.full

Internet

https://drc.bmj.com/content/10/6/e002988.full

Similar Items